Method of producing treated ginseng with increased amount of ginsenoside rg5

FIELD: medicine.

SUBSTANCE: 1-3-fold amount of water is added to mixed five-seven-year old ginseng with further treatment at pressure 1.20 to 1.50 kg/cm2 if ginseng is rind, or 2.30 to 3.00 kg/cm2 if ginseng is covered with rind at 110-130°C during 1 to 5 hours to produce treated ginseng thereafter extracted with mixed methanol and methylene chloride in ratio 0.6:1.40 to 1.2:0.8 by boiling extraction method with using a backflow condenser during 1 hour to approximately two days. The mixture is filtered that is followed with filtrate concentration and drying. The pharmaceutical composition for treatment or prevention of stomach, liver, lung, skin or breast cancer contains ginseng extract. Foodstuff contains ginseng extract.

EFFECT: product with high content of ginsenoside Rg5.

6 cl, 3 ex, 3 tbl, 14 dwg

 

The technical field to which the invention relates.

The present invention relates to a method for differently processed ginseng to achieve a higher number of ginsenoside Rg5. More specifically the present invention relates to a method for producing a processed product of ginseng and its extract, which contains an increased amount of ginsenoside Rg5 by processing of ginseng in a specific range of pressure and temperature.

The level of technology

Found that ginseng increases nonspecific resistance to physiological stress and has a supporting effect on the homeostasis of the person along with other potent pharmacological activities, i.e. ease the symptoms of hypertension, enhances the activity of insulin, reduces the activity of glucose in the blood, has a stimulating effect on RNA synthesis in the liver, the metabolism of protein, glucose and lipid or possesses anticancer activity.

There are many plants of the genus Panax genus belonging to Araliaceae, such as Panax ginseng, common or cultivated in the far East Asia, Panax quinquefolia in America and Canada, Panax notoginseng in China, Panax trifolia in the Eastern region of North America, Panax japonica in Japan, China and Nepal, Panax pseudoginseng in Nepal, Panax vietnamensis in Vietnam, Panax elegatior, Panax wangianus and Panax bipinratifidus etc.

Three types of products is that of ginseng are commercially suitable, ie ginseng four, five and six years of age, and described that the most potent among them is the product of ginseng six years of age, grown until the autumn. The skin is deprived of the skin ginseng contains a particularly large amount of saponin, which shows high activity.

Ginsenoside saponins isolated from ginseng with skeleton gamerboy resin associated with several sugars differ from saponins isolated from other plants. Specifically described that ginseng contains approximately 30 species sapojnikova ingredients, especially ginsenoside Rb1, Rb2, Rc, Rd, Rg, Re, etc. as the main components. Such saponine compounds exhibit different pharmacological activity and efficiency according to their chemical structure and among them ginsenoside Rg5 widely described recently as a drug due to its strong immunostimulating activity and vasodilating activity, anticancer activity, activity protect neuronal cells, etc.

Currently, conventional ginseng trying to process so as to obtain a higher efficiency or suitability by changing patterns of ginseng saponins during processing.

In Korean patent No. 10-0192678 described a method of obtaining arabtimesonline, obtained by high-temperature treatment, with a high content of ginsenoside Rg5, which received the processed ginseng has increased efficiency, different from the original form of ginseng. However, the processing method cannot provide information regarding the correlation between the change in the content of Rg5 and changes in temperature and internal pressure, and in the way you want toxic organic solvent, such as butanol.

The authors of the present invention conducted intensive research on new processing method to obtain safe and homogeneous product ginseng. The study authors found a new method of processing of obtaining pharmacologically potent product ginseng, which has a higher content of ginsenoside Rg5, confirmed by conventional ginseng and processed product ginseng, described in the prior art, and as a result, the authors obtained the present invention.

Disclosure of inventions

Technical issues

Accordingly, the present invention is to provide a method of handling obtaining pharmacologically potent ingredients of ginseng, which have high content of ginsenoside Rg5.

Technical solution

According to Nast is ademu the invention proposes a method of processing of obtaining pharmacologically potent product and ginseng extract from it, in which the maximum content of ginsenoside Rg5 different treatment ginseng in selected intervals of pressure and temperature.

Specifically, the present invention provides a processing method of obtaining pharmacologically potent product ginseng, which includes stages: add approximately 1-3 times the weight of water based on the weight of the ginseng, the material of ginseng five years of age, preferably the material of ginseng six years of age; and treatment under the internal pressure in the range from 1.10 to 4.00 kg-force/cm2preferably, 1,20-1,50 kg-force/cm2in the case of the cleansed skin of ginseng or of 2.30-3.00 kg-force/cm2in the case of ginseng with skins, in the temperature range from about 70 to 150°C., preferably at 110-130°C for a time period in the range from 1 to 5 hours, preferably about 2 hours to obtain the desired processed ginseng, has a large number of ginsenoside Rg5.

Obtained through the above processing method in the case of ginseng, devoid of skin, the end product of the ginseng of the present invention contains a significantly larger number of ginsenoside Rg5, approximately two to five times, specifically approximately 4.4 times more than the processed ginseng obtained by the method described in karasmontana No. 10-0192678.

Obtained through the above processing method in the case of ginseng with skins is the end product of the ginseng of the present invention contains a significantly larger number of ginsenoside Rg5, approximately two to five times, specifically approximately 3.3 times more than the processed ginseng obtained by the method described in Korean patent No. 10-0192678.

In the present invention is also a method for extracting the processed ginseng extraction, consisting of stages, which includes the extraction treated material ginseng obtained in the above stage, the mixture of organic solvents, preferably a mixture of methanol and methylene chloride, more preferably a mixture of methanol and methylene chloride, mixed in the range of ratios from 0,60:of 1.40 to 1.20:to 0.80, more preferably a mixture of methanol and methylene chloride is about 1:1 (V/V)by the method of extraction by boiling under reflux over a period of time in the interval from 1 hour to two days, preferably more than 1 hour; filtering to obtain a filtrate, concentrating the filtrate to remove the remaining solvent and drying to obtain potent ginseng extract having a large number of ginsenoside Rg5.

In the present invention, preferably used is described in the above "material ginseng" six years of age, because ginseng the age of six contains a higher amount of ginsenoside Rg5 than ginseng the age of four, as confirmed by the following experiments conducted by the authors of the present invention.

Described here, the material of ginseng includes its leaves, which as described are unused, and the root of ginseng, since the present invention argues that the treated leaves of ginseng of the present invention contain an amount of ginsenoside Rg5 equivalent to the number in the root of ginseng, which is confirmed by the following experiments conducted by the authors of the present invention.

The thus treated ginseng or its extract can be dried in a known manner with the receipt of dried processed ginseng, for example dried at lower temperatures, i.e. below 70°C, over a period of time in the range from about 48 to 60 hours or method of drying by freezing, and can be further processed by grinding or turning into powder with a smaller particle size, preferably with a size in the range from about 50 to 200 micrometers, a method well known in this field, if required, to obtain commercially usable end product, such as a capsule, tablet, etc, using pharmaceutically acceptable carrier or adjuvant.

The proposed processed ginseng worthless invention contains an increased amount of ginsenoside Rg5, with a strong pharmacological activity, such as vasodilating activity, immunostimulirutuyu activity, anticancer activity, the activity of neuronal cell protection, etc., in particular anticancer activity.

In addition, the present invention also provides a pharmaceutical composition comprising the extract of ginseng obtained by the above described processing method, and a pharmaceutically acceptable carrier or adjuvant for the treatment or prevention of cancer, and the method of the present invention can provide the maximum content of ginsenoside Rg5 through selected intervals of pressure and temperature.

Specified herein, the term "cancer" includes various forms of cancer such as stomach cancer, liver cancer, lung cancer, cervical cancer, skin cancer or breast cancer, especially skin cancer.

Ginseng extract of the present invention has high antitumor activity and, therefore, the pharmaceutical composition of the present invention can be used to treat or prevent various cancers.

Now the image is giving also offers the use of ginseng extract, obtained by the above described processing method for the manufacture medicines used in the treatment or prevention of various forms of cancer such as stomach cancer, liver cancer, lung cancer in men and cervical cancer, skin cancer, cancer of the breast.

According to another aspect of the present invention a method of treating or preventing various forms of cancer such as stomach cancer, liver cancer, lung cancer in men and cervical cancer, breast cancer, where the method includes the introduction of a therapeutically effective amount of the ginseng extract, obtained as described above processing.

The composition of the invention may additionally include the conventional carrier, adjuvant or diluent according to the applied method. Preferably, these media are used as a specific substance according to the application method and application, but is not limited to this. Appropriate diluents listed in the publication Remington''s Pharmaceutical Science (Mack Publishing co, Easton PA).

Following below, the methods of preparation drugs and excipients are only illustrative and in no way limit the invention.

The composition according to the present invention can be prepared as a pharmaceutical composition comprising the pharmaceutical and food & the automatic acceptable carriers, adjuvant or diluents, for example lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, aritra, ▫ maltitol, starches, resins acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. The preparations may additionally contain fillers, antiglomerular agents, lubricating agents, moisturizing agents, corrigentov, emulsifiers, preservatives and the like. Compositions of the invention can be produced so as to provide rapid, prolonged or delayed release of the active ingredient after their introduction into the patient by applying any of the techniques well known in the field.

For example, compositions of the present invention can be soluble in oils, propylene glycol or other solvents that are usually used to obtain injections. Suitable examples of carriers include physiological saline, propylene glycol, ethanol, vegetable oils, isopropylmyristate etc., but are not limited to this. For topical use the compounds of the present invention can be produced in the form of ointments or creams.

Pharmaceutical preparations containing the above composition can be produced in any of the Orme, such as oral dose form (powder, latinor-pulves, granule, tablet, capsule, soft capsule, the drug in water, syrup, elixirs pill, solution, powder, sachet, granule), or the preparation for topical application (cream, ointment, lotion, gel, balm, patch, paste, solution, spray, aerosol and the like), or an injectable preparation (solution, suspension, emulsion, injection).

The composition of the present invention in the pharmaceutical formulations can be applied in the form of their pharmaceutically acceptable salts, and also you can apply only one or in appropriate Association, as well as in combination with other pharmaceutically active compounds.

Required proposed dose of the extract or the composition varies depending on the condition and weight of the subject, the severity of the condition, drug form, route and period of application and can be selected by the person skilled in the art. However, in order to obtain the desired effects, it is generally recommended to apply the amount of the extract of the invention or compounds of the present invention in the range of 0.2-200 mg/kg, preferably 2-100 mg/kg according to the index weight/day. Dose can be administered once or divided into several doses per day. Based on the composition of complex herbal composition will be present in the range of from 0.01 to 80% of m is SS, preferably 0.5 to 50 wt%, considering the total weight of the composition.

The pharmaceutical composition of the present invention it is possible to introduce the subject animal, such as mammals (rat, mouse, Pets or people) in different ways. There are all ways of introducing, for example, can be administered orally, rectally or by intravenous, intramuscular, subcutaneous, intradermal, intrarectal, epidural or intracerebroventricular injection.

In addition, another objective of the present invention to provide a healthy food product containing the above-mentioned extract, obtained by the above processing method, and a nutritionally acceptable additive for the prevention of various diseases.

The above composition can be applied to prevent or relieve symptoms of various cancers. For the purpose of preventing or relieving the symptoms of various cancers, the number of the above extract can usually be in the range from about 0.1 to 15 mass/mass %, preferably 1-10 mass/mass % of the total mass of the food product composition of healthy food and 1-30 g, preferably 3 to 10 g with respect to 100 ml of the composition of a healthy drink. The composition of the present invention in which the contain subjects animals, such as mammals (rat, mouse, Pets or people) in different ways. There are all ways of introducing, for example, can be administered orally, rectally or by intravenous, intramuscular, subcutaneous, intradermal, intrarectal, epidural or intracerebroventricular injection, in any form, such as oral dosage form (powder, latinor-pulves, granule, tablet, capsule, soft capsule, syrup, elixirs pill, solution, powder, sachet or granule).

To ensure a composition of the invention useful for the health drink of the present invention contains the above extract as an important component in the given ratio, there are no particular restrictions on the other liquid component, where the other component may be different deodorant or natural carbohydrates, etc. such as in the conventional drink. Examples of the above-mentioned natural carbohydrates are monosaccharides, such as glucose, fructose, etc.; a disaccharide such as maltose, sucrose, etc.; common sugars such as dextrin, cyclodextrin, and sugar in the form of alcohol, such as xylitol and aritra etc. as another deodorant than the above-mentioned components, can benefit from using natural deodorant such as thaumatin, stevia extract, such as levelized A, glycyrrhizin is so, and synthetic deodorant, such as saccharin, aspartame, etc. the Number above the natural carbohydrate is usually in the range from about 1 to 20 g, preferably 5 to 12 g with respect to 100 ml of this composition of the drink.

Other components than the above-mentioned composition, represent different nutrients, vitamin, mineral or electrolyte, synthetic Corrientes agent, a coloring agent and improving agent in the case of cheese, chocolate, etc., pectic acid and its salts, alginic acid and its salt, organic acid, protective colloidal binder, agent, regulating pH, stabilizer, preservative, glycerin, alcohol, carbonitride agent used in the saturated carbon dioxide drink, etc. Other component than the above components may be fruit juice to get natural fruit juice drink with fruit juice and vegetable drink in which the component can be used independently or in combination. The ratio of the components is not so important, but it usually is in the range from about 0 to 20 mass/mass % for 100 mass/mass % of the present composition.

Examples of additives suitable for the product, which includes the above extract, represent different food, drink, gum, vitamin complex, the field is hydrated for health food product and the like.

For the person skilled in the art it will be obvious that various modifications and variations can be made in the compositions, the use of drugs of the present invention without departure from the essence or scope of the invention.

Beneficial effects

The method of obtaining the processed ginseng according to the present invention can provide an increased amount of ginsenoside Rg5 exhibiting various pharmacological actions, by applying the method selected specific pressure and temperature, and composition comprising the processed ginseng and its extracts can be used as a medicine or healthy food product for the prevention or treatment of various diseases, especially cancer.

Brief description of drawings

The above and other objectives, features and other advantages of the present invention will be certainly more understandable from the following detailed description, are included in conjunction with the accompanying drawings, in which:

figure 1 shows the result of LC and mass spectrum of the extract of ginseng (G1-1);

figure 2 shows the result of LC and mass spectrum of the extract of ginseng (G1-2);

figure 3 shows the result of LC and mass spectrum of the extract of ginseng (G1-3);

figure 4 shows the result of LC and mass spectrum of the extract of ginseng (G1-4);

figure 6 shows the result of LC and mass spectrum of the extract of ginseng (G1-6);

7 shows the result of LC and mass spectrum of the extract of ginseng (G1-7);

on Fig shows the result of LC and mass spectrum of the extract of ginseng (G2-1);

figure 9 shows the result of LC and mass spectrum of the extract of ginseng (G2-2);

figure 10 shows the result of LC and mass spectrum of the extract of ginseng (G2-3);

figure 11 shows the result of LC and mass spectrum of the extract of ginseng (G3);

on Fig shows the result of LC and mass spectrum of the extract of ginseng (G4);

on Fig shows the result of LC and mass spectrum ginseng extract (STD);

on Fig shown anticancer activity of ginseng extract.

Description of the preferred option of carrying out the invention

The present invention is more specifically explained by the following examples. However, it should be clear that the present invention is in no way limited to these examples.

Option of carrying out the invention

Comparative example 1. Receiving the processed ginseng according to the method described in KR patent No. 10-0192678

Not and cut into pieces 1 kg of the roots of Panax ginseng was placed in a device for the extraction of crude drugs (20L/Kukje-kigong, Korea) and then heated with steam at 130°C for 2 hours. Steamed ginseng dried at 50-60°C and sprayed what a fine powder with a particle size of powder in the range of 50-200 micrometers to obtain 195 g of powder of ginseng, used as a comparative sample (denoted below as "STD").

Example 1. Getting proposed invention ginseng extract without the skin

1-1. Obtaining ginseng extract (G1-1)

Air-dried and cut into pieces 300 g of Panax ginseng roots by age six, without skin, immersed in 600 ml of distilled water was placed in a device for the extraction of crude drugs (20L/Kukje-kigong, Korea) and then was heated, while maintaining the internal temperature in the range from 126°to 130°C. and the internal pressure in the range from 1.4 to 1.5 kg-force/cm2within 2 hours. The processed ginseng extracted from water and dried at 60-70°C, and crushed into a fine powder with a particle size of powder in the range of 50-200 micrometers with getting 255 g of ginseng powder (yield: 85.0 per cent), used as a sample (denoted below as "G1-1").

1-2. Obtaining ginseng extract (G1-2)

All methods, except for changes in the internal temperature in the range from 103°C to 107°C and the internal pressure in the range from 1.40 to 1.50 kg-force/cm2was similar to the method described in example 1-1, to obtain 280 g of ginseng powder (yield of 93.3%), used as a sample (denoted below as "G1-2").

1-3. Obtaining ginseng extract (G1-3)

All methods, except the changes in the internal temperature in the range from 110°C to 114°C. and the internal pressure in the range from 1.40 to 1.50 kg-force/cm 2was similar to the method described in example 1-1, to obtain 260 g of ginseng powder (yield: 86.7 per cent), used as a sample (denoted below as "G1-3").

1-4. Obtaining ginseng extract (G1-4)

All methods, except for changes in the internal temperature in the range from 126°to 130°C. and the internal pressure in the range of from 1.85 to 2.00 kg-force/cm2was similar to the method described in example 1-1, with the receipt of 245 g of ginseng powder (yield: 81.7 per cent), used as a sample (denoted below as "G1-4").

1-5. Obtaining ginseng extract (G1-5)

All methods, except for changes in the internal temperature in the range from 126°to 130°C. and the internal pressure in the range of 2.30 to 2.50 kg-force/cm2was similar to the method described in example 1-1, to obtain 240 g of ginseng powder (yield: 80%), used as a sample (denoted below as "G1-5").

1-6. Obtaining ginseng extract (G1-6)

All methods, except for changes in the internal temperature in the range from 126°to 130°C. and the internal pressure in the range from 2.80 to 3.00 kg-force/cm2was similar to the method described in example 1-1, to obtain 235 g of ginseng powder (yield: 78.3%of)that is used as the sample (indicated below as "G1-6").

1-7. Getting ex is rakta ginseng (G1-7)

All methods, except for changes in the internal temperature in the range from 133°to 137°C. and the internal pressure in the range of from 3,30 to 3.50 kg-force/cm2was similar to the method described in example 1-1, with the receipt of 162 g of ginseng powder (yield: 54.0 per cent), used as a sample (denoted below as "G1-7").

Example 2. Getting proposed invention extracted ginseng with skins

2-1. Obtaining ginseng extract (G2-1)

Air-dried and cut into pieces 300 g of roots of Panax ginseng with skins, six years of age, immersed in 600 ml of distilled water was placed in a device for the extraction of raw drugs (20L/Kukje-kigong, Korea) and then was heated, while maintaining the internal temperature in the range from 126°to 130°C. and the internal pressure in the range from 2.80 to 3.00 kg-force/cm2within 2 hours. The processed ginseng extracted from water and dried at 60-70°C, and crushed into a fine powder with a particle size of powder in the range of 50-200 microns, with getting 249 g of ginseng powder (yield: 83.0 per cent), used as a sample (denoted below as "G2-1").

2-2. Obtaining ginseng extract (G2-2)

All methods, except for changes in the internal temperature in the range from 126°to 130°C. and the internal pressure in the range from 1.40 to 150 kg-force/cm 2was similar to the method described in example 2-1, to obtain 260 g of ginseng powder (yield: 86.7 per cent), used as a sample (denoted below as "G2-2").

2-3. Obtaining ginseng extract (G2-3)

All methods, except for changes in the internal temperature in the range from 133°to 137°C. and the internal pressure in the range of from 3,30 to 3.50 kg-force/cm2was similar to the method described in example 2-1, to obtain 220 g of ginseng powder (yield: 73.3 per cent), used as a sample (denoted below as "G2-3").

Example 3. Getting proposed invention ginseng (G3)

All methods, except that used 300 g round Panax ginseng without skin, the age of four and the conditions of extraction when the internal temperature and the internal pressure set in the range from 126°C to 130°C and from 1.40 to 1.50 kg-force/cm2was similar to the method described in example 1, obtaining 236 g of ginseng powder (yield: 78,7%), used as a sample (denoted below as "G3").

Example 6. Getting proposed invention ginseng (G4)

All methods, except that used 300 grams of ginseng second grade age six peeled and conditions of extraction when the internal temperature and internal pressure established in the inter the ale from 126°C to 130°C and from 1.40 to 1.50 kg-force/cm 2was similar to the method described in example 1, to obtain 250 g of ginseng powder (yield: 83,3%), used as a sample (denoted below as "G4").

Experimental example 1. Analysis of the component and its content

Sample preparation

20 ml of methanol and 20 ml of methylene chloride was added to 2 g of each of the samples obtained in comparative example and examples, and subjected to extraction by boiling under reflux for 60 minutes, the Solution was cooled, filtered to remove insoluble substances and supernatant concentrated with getting his balance. The mass of each of the final sample extract was as follows: 0,183 g (G1-1), 0,110 (G1-2), 0,160 (G1-3), 0,154 g (G1-4), 0,131 g (G1-5), 0,192 g (G1-6), 0,079 g (G1-7), 0,148 g (G2-1), 0,070 (G2-2), 0,061 g (G2-3), 0,079 g (G3)0,083 (G4) and 0.124 g (STD respectively.

Analysis by the method of gas chromatography / mass spectrometry

Solvent mixture of methanol and methylene chloride (1:1) was added to the test samples obtained in stage 1-1, in the amount of 18.3 ml (G1-1), and 11.0 ml (G1-2), 16.0 ml (G1-3), of 15.4 ml (G1-4), of 13.1 ml (G1-5), and 19.2 ml (G1-6), and 7.9 ml (G1-7), of 14.8 ml (G2-1), 7,0 ml (G2-2)and 6.1 ml (G2-3), and 7.9 ml (G3), and 8.3 ml (G4) and 12.4 ml (STD), respectively, in such quantity that installed the final concentration of each of the samples was identical with each other. 3 ml of each sample was subjected to microcentrifuge with a speed of 1300 rpm for 15 minutes 5 ICRI is liters each supernatant introduced into the device for gas chromatography / mass spectrometry under conditions shown in table 1, and the results are presented in figure 1-13.

Table 1
Analysis by the method of gas chromatography / mass spectrometry
ModelAGILENT:1100 Series LC/MSD
ColumnMicrobonda Pak-NH2; 3,0×390 mm (Waters)
The mobile phaseCH3CN:H2O:i-PrOH=80:5:15
The flow velocity1.5 ml/min
The wavelength for detection280 nm

Comparison results for each sample are shown in table 2.

As can be seen in table 1, confirmed that the number of ginsenoside Rg5 obtained in the examples, approximately 4.4 and 3.3 times higher than the amount in the comparative example.

In addition, it is confirmed that the method of obtaining of the present invention is superior to the method previously known in this field.

Table 2
SampleRg5 (peak area)Mac is and residue (g) The area of turning/gRg5 (multiplicity)
G1-1462,176970,18384,64,4
G1-277,647430,1108,50,4
G1-3241,690510,16038,72,0
G1-4265,285980,154of 40.92,1
G1-5250,037370,13132,81,7
G1-6280,658260,19253,92,8
G1-7276,190830,07921,81,1
G2-1431,974820,148 63,93,3
G2-2194,581480,07013,60,7
G2-3108,809070,0616,60,3
G3222,558470,07917,60,9
G4225,629610,08318,71,0
STD156,849440,12419,41,0

In addition, the authors of the present invention conducted a study to determine the optimum conditions of extraction, in particular the ratio in the mixture system of the extraction solvent by changing the relationship of the volumes in a mixture of methanol and methylene chloride in the range of from 0,60:of 1.40 to 1.20:0,80 and as a result have found that the most effective condition of extraction from this solvent mixture of methanol and methylene chloride (1:1), the constant electrical conductivity that is is 20,75.

According to these authors argue that the most effective system of extraction solvent to obtain a higher number of ginsenoside Rg5 is a mixture solvent of methanol and methylene chloride (1:1) to obtain a higher number of ginsenoside Rg5.

Experimental example 2: Determination of anticancer activity

Anticancer activity of ginseng extract containing high amount of ginsenoside Rg5 obtained in experimental example 1, was determined by the following experiments.

Sample preparation

Ginseng extract of the invention, extracted with a mixture solvent of methanol and methylene chloride (1:1)obtained by the method corresponding to the method described in example 2-1 was used as the test sample (denoted below as "GMM"), when dissolved in distilled water (5 mg/ml).

Test animals

Mice C57BL/6 weeks of age weighing 10-15 g, dissolved in identical conditions classified into two groups, ie, 80 mice in the test group and 20 mice in the control group. The test group was treated cell line B16 melanoma to cause cancer and the control group were not treated. The test group optionally classified into two groups, i.e. the test group (1)treated only distil the new water and the test group (2), the processed amount of the extract GMM invention in week 5, and the control group are also classified into two groups, i.e. the control group (1)treated only with distilled water, and a control group, (2)treated with an equivalent amount of the extract of the invention on week 5.

Test method

Mice C57BL/6 weeks of age, weighing 10-15 g, dissolved in identical conditions, were given free access to drinking solution containing the extract of the invention obtained in the above stage in the control group (2) and test group (2) after delectatio mice (four weeks after birth). Cells were injected with B16 melanoma in the abdominal Department of mice subcutaneously in groups of cancer surveillance.

Cells B16 melanoma has subculturally in the incubator with CO2within 1 week and the floating cells, diluted environment RMPI 1640 containing 10% fetal calf serum, with the prescribed concentration of 1×106cells/ml, were injected with 0.1 ml.

The rate of cancer growth and survival period was determined by the size of the cancer every five days after injection, and the survival time of each group. The growth rate of cancer compared with the mass of cancer and the result was calculated, following the mathematical calculation according to the formula 1.

Formula 1 for mathematical calculation:

Those who t-result

As you can see in Fig, 1 week at 55% of the mice were observed cancer in the test group (1), at the same time in the test group (2) - 25% of mice. On day 12 and day 17 in 80% and 95% of the mice were observed cancer in the test group (1), respectively, at the same time, 35% and 42.5% in the test group (2), respectively. On the 24 day at 100% of the mice were observed cancer in the test group (1), at the same time - 52,5% in the test group (2).

As can be seen in table 3, showed no significant differences between the average mass of cancer at 1 week after injection of cancer cell lines (average weight cancer 0.1 g), however, the difference between the average mass of cancer between the test groups gradually increased, i.e. the average mass of cancer in the test group (1) and (2) was 0.4 g and 0.3 g on day 12, and 1.8±0.3 and 1.5±0.2 g on the 17th day of 5.1±0.2 g and 3.3±1.0 g on day 22 and 22.4±5,3 g and 9.8±2.1 g on day 57, respectively.

In addition, not found in the death of mice in the test group (1) and (2) on day 12, at the same time, one mouse died in the test group (1) on the 17th day. 85% of mice in the test group (2) survived for more than 42 days after injection of cancer cells and approximately 50% of mice survived in the test group (1). 60 day all the mice in the test group (1) was killed at the same time, 60% of mice in the test group (2) had survived.

td align="center" namest="c6" nameend="c9"> The survival rate (%)
Table 3
TestThe cancer mass (g)
group/dayday 7day 1217 dayday 2257 dayday 1217 dayday 42day 60
(1)0,10,41,8±0,35,1±1,222,4±5,310097,5500
(2)0,10,31,5±0,23.3V±1,09,8±2,11001008560

Accordingly, it is confirmed that ginseng extract obtained by the method of the present invention showed potent will protivorechu activity, since the method of the present invention can provide an increased amount of ginsenoside Rg5 exhibiting potent anticancer activity.

Exp the pilot example 3: Test toxicity

Methods

Testing acute toxicity in mice SD (with an average body weight of 25±5 g) and rats Sprague-Dawley (235±10 g) were produced with the use of the extract of the invention. Each group, consisting of 3 mice or rats were administered orally with 1 g/kg of test sample or solution (0.2 ml, intraperitoneally) and were followed for 24 hours.

Results

Not found handling-related effects on mortality, clinical signs, changes in body weight and total data in any group or any gender and confirmed that LD50oral administration of the extract of the invention was not more than 1 g/kg, These results indicate that the extract of the invention obtained in the present invention, was potent and safe.

Hereinafter will be described the methods of preparation of medicines and types of excipients, but the present invention is not limited to their enumeration.

Representative examples of drugs described below.

The drug in powder form

The dried powder (G1-1) in example 1, 20 mg

Lactose, 100 mg

Talc, 10 mg

The drug in powder form was obtained by mixing the above components and filling sealed packaging.

The drug is in tablet form

The dried powder (G1-1) in example 1, 10 mg

Corn starch 100 mg

Lactose, 100 mg

The drug is in tablet form was obtained by mixing the above components and forming tablets.

The drug is in the form of capsules

The dried powder (G1-1) in example 1, 10 mg

Crystalline cellulose, 100 mg

Lactose, 100 mg

Magnesium stearate 2 mg

The drug is in tablet form was obtained by mixing the above components and filling gelatin capsules by the way, accepted for gelatin preparation.

The drug is in the form of injections

Extract (G2-1) in example 2, 10 mg

Distilled water for injection optimum amount

Agent for regulating the pH, the optimal number

The drug is in the form of injections received by dissolving active component, establishing a pH of about 7.5 and then filling all the components in 2 ml vials and sterilized by the way, common for drugs in the form of injection.

Liquid drug

Extract (G2-1) in example 2, 0.1 to~80 g

Sugar, 5~10 g

Citric acid, 0.05 to~0,3%

Caramel, 0,005~0,02%

Vitamin C, 0,1~1%

Distilled water, 79~94%

CO2, gas 0,5~0,82%

Liquid preparation was obtained by dissolving active component, the content of all components and sterilization method, the conventional liquid drug.

In the preparation of healthy food

Extract (G2-1) in example 1, 1000 mg

Vitamins to anti scar is fair mixture, the optimal number

Vitamin a, acetate, 70 mg

Vitamin E 1.0 mg

Vitamin B1, 0.13 mg

Vitamin b2, 0.15 mg

Vitamin b6, 0.5 mg

Vitamin b12, 0.2 mg,

Vitamin C, 10 mg

Biotin, 10 mg

Nicotinic acid amide, 1.7 mg

Folic acid, 50 mg

Calcium salt of Pantothenic acid, 0.5 mg

A mixture of minerals, the optimal number

Ferric sulfate, 1.75 mg

Zinc oxide 0,82 mg

Magnesium carbonate to 25.3 mg

The monokaliy, 15 mg

The dicalcium phosphate, 55 mg

Potassium citrate, 90 mg

The calcium carbonate 100 mg

Magnesium chloride, 24,8 mg

The above-mentioned vitamin and mineral blend can be modified in several ways. Such variations are not regarded as a departure from the essence and scope of the present invention.

Medication in the form of a healthy drink

Extract (G2-1) in example 2, 1000 mg

Citric acid, 1000 mg

Oligosaccharide, 100 g

Apricot concentrate, 2 g

Taurine 1 g

Distilled water, 900 ml

Medication in the form of a healthy drink was obtained by dissolving active component, by mixing, with stirring at 85°C for 1 hour, filtered and then filling all the components in 1000 ml vials and sterilized by the way, common for the drug in the form of a healthy drink.

As described thus the ohms of the invention it will be obvious what is presented in the invention can be modified in several ways. Such variations are not regarded as a departure from the essence and scope of the present invention and all such modifications as would be obvious to the person skilled in the art are intended for inclusion in the next volume further claims.

Industrial applicability

The method of obtaining the processed ginseng according to the present invention can provide an increased amount of ginsenoside Rg5 possessing various pharmacological activities when used in the way you choose a specific pressure and temperature, and the composition comprising the processed ginseng and its extracts can be used as a drug or beneficial health food for the prevention or treatment of various diseases, especially cancer.

1. A method of obtaining a processed ginseng extract, providing stage: add 1-3 times the mass of water to the material of ginseng five years of age, the processing when the internal pressure in the range from 1.20 to 1.50 kg-force/cm2in the case of ginseng without skin or 2.30 to 3.00 kg-force/cm2in the case of ginseng with skins in the temperature range from 110 to 130°C., for from 1 to 5 h to obtain the processed ginseng extraction processed is of Angsana mixture of methanol and methylene chloride, with their ratio from 0,60:of 1.40 to 1.20:0.80, the method of extraction by boiling under reflux for from 1 hour to two days, filtering to obtain a filtrate, concentrating the filtrate to remove the remaining solvent and drying to obtain the specified ginseng extract.

2. The method according to claim 1, where specified material ginseng is a ginseng the age of six without skin or ginseng with skins.

3. Pharmaceutical composition containing ginseng extract obtained by the method according to claim 1 and a pharmaceutically acceptable carrier or adjuvant for the treatment or prevention of cancers such as stomach cancer, liver cancer, lung cancer, skin cancer or breast cancer.

4. The pharmaceutical composition according to claim 3, where the specified composition is made in the form of powder, granules, tablets, capsules, soft capsules, aqueous solution medicines, syrup, elixir, oral solution, powder, sachet, granule, cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol or injection.

5. Healthy food product containing extract obtained by the method according to claim 1, having potent anti-cancer activity, and nutritionally adequate food Supplement.

6. Healthy food product according to claim 5, where indicated what healthy food is made in the form of tablets, capsules, powder or granules.
Priority items:

12.04.2005 - claims 1, 2;

11.04.2006 - p-6.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to pharmacy. Alchemilla herb milled to particle size 3 mm is extracted with treated water in ratio raw material-extractant 1:10 by expedited fraction maceration in three-staged heating to 90°-95°C: within 1 hour, 45 minutes and 30 minutes. The combined extracts are settled, filtered, decanted, softened by steam and dried in a flash drier.

EFFECT: invention allows representing the specified object matter.

6 tbl

FIELD: chemistry.

SUBSTANCE: invention refers to food industry. Method of producing extractive substances of Siberian cedar seed coat includes milling the seed coat that is followed with two-stage extraction to precipitate end product. The seed coat is milled to particle size 100-200 mcm. The basic extraction is enabled with 40% aqueous-soda liquor within 25-30 minutes. After extraction cake is removed, it is additionally extracted with aqueous-soda liquor concentrated 2.0-2.5 g/l within 25-30 minutes. The basic and additional extraction are enabled in microwave electromagnetic at microwave power 300-400 W/h/kg, temperature 80-90°C, the hydraulic index 8-10 dm3/kg. After soda extract is neutralised, it is mixed with the basic extract and concentrate.

EFFECT: intensified process and higher yield of extractive substances.

2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention concerns pharmacy. An extract from vegetative raw materials is obtained, extract clearing, it's freezing and drying at temperature from -52 to -58°C and pressure from 1 to 3 Pa. And extract drying is conducted to residual humidity not more by than 5%.

EFFECT: invention allows receiving a product in the powdery condition, providing exact dosage with conservation of properties of biologically active substances.

2 cl, 2 ex, 4 dwg

FIELD: technological processes.

SUBSTANCE: invention is related to technology of extraction processes. Material and absorbent are alternately installed in the form of layers along internal channel of container, dissolvent is supplied into internal channel of container under high pressure, previously determined component is extracted from material into dissolvent, previously determined component contained in dissolvent is absorbed into absorbent to remove component. Device for extraction of component from material comprises container with internal channel, areas for material filled by material, and areas for absorbent filled by absorbent and installed in alternating order in the form of layers in internal channel of container, and circulation channel for dissolvent that is partially formed from internal channel of container, where previously determined component that is contained in material is extracted into dissolvent, and previously determined component contained in dissolvent is absorbed into absorbent for removal.

EFFECT: invention makes it possible to realise the mentioned purpose.

7 cl, 5 tbl, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns processing technology for raw medical, essential-oil and aromatic spice materials. Raw Echinacea purpurea material is reduced extracted by carbon dioxide at 10-25°C and 4.5-6.5 MPa pressure for 50-110 minutes. Further four-grade counterflow extraction of cake is performed by distilled water at 75-95°C at cake to water ratio of 1:10 to obtain autonomous or combined extracts. 15% alcohol solution of CO2 extract is prepared and further blended with water extract at 1:3 ratio respectively. Water extract is preserved by ethyl alcohol to obtain 15% extract.

EFFECT: increased extraction of lipid and water soluble bioactive substance complex from raw Echinacea purpurea material.

3 cl, 4 ex, 6 tbl, 3 dwg

FIELD: chemistry.

SUBSTANCE: invention concerns organic chemistry, particularly method of dihydroquercetin extraction from larch wood, and can be applied in chemical and pharmaceutical industry, medicine, food industry. Invention claims method of dihydroquercetin extraction from milled larch wood by extraction with organic solvent. Wood is milled into chips, extraction is performed gradually in several stages in at least two extractors, maintaining continuous circulation of one minimal extraction solvent volume required for chip submersion in liquid medium at each stage, simultaneously generating low-frequency oscillating field at temperature close to boiling point of solvent, with further hot extract transport after completion of process at one stage in one extractor volume to the next extraction stage, each time adding new extraction solvent in amount equal to solvent outflow with extracted chips. Then each extracted chip portion is flushed with one minimal solvent volume required, extracts from the last n extraction and flushing stages are combined into one volume, solvent is separated from it, remains are concentrated, and dihydroquercetin is extracted. Invention also claims aggregate for dihydroquercetin extraction from larch wood, including feeding tank, heater, extraction solvent collector and at least one extraction solvent processing lines with further dihydroquercetin extraction from it, each line including inlet and outlet valves, extraction reactor and pulp pump and carrying solvent vapour condenser, heater for solvent heating and low-frequency oscillator in the form of diaphragm pump mounted on pipeline. Each extractor is active periodically and is connected to feeder tank outlet by one of inlets, to extract feed unit by the other inlet over first inlet valve, to condenser inlet by one of outlets. Condenser outlet is connected over second inlet valves to another inlet of each extractor, the other extractor outlet connected to third inlet of each extractor over a sequence of heater, pump, oscillator and third inlet valve. Third extractor inlets are connected to extraction solvent collector over third pump and fourth valve.

EFFECT: reduced extraction agent expenditure.

5 cl, 2 dwg, 3 tbl, 2 ex

FIELD: mechanics.

SUBSTANCE: invention is used for solid-liquid extraction to extract components, extracts, juices from solid-phase materials, low-succulent and succulent vegetable and animal raw materials, hydrobionts, and dispersion fluids and pulps. The unit is comprised of a grinder, infuser, decanting thickener for infused pulp, mixer, shell-and-tube tube-in-tube extractor with convective permeable inner tube and pulse system and decanting thickener for extracted pulp. The extractor shell is separated by longitudinal baffles in even number of channels with extractant inlet nozzles on one end and extractant discharge nozzles on the other end. Pulp is fed into the tube and extractant is fed in counter-flow into the extractor shell channels. The pulse system creates alternating differential pressures between the longitudinal channels of the extractor shell. The infuser and mixer are connected by return pipe to the extract outlet of the extractor shell, and liquid-phase outlet of the extracted pulp decanting thickener is connected to fresh extractant inlet of the extractor. Options for extraction of moderately grindable raw materials, such as drupaceous and seed raw materials and grapes, include auger with rotary drive in the inner tube of the extractor. Solid-liquid phase extraction method includes raw materials grinding and mixing with liquid for fluid pulp formation, counterflow convective mass transfer between pulp and extractant flows in adjacent channels with permeable walls while creating alternating differential pressures between them for repeated transverse liquid-phase exchange to produce extracted pulp and extractant, extracted pulp thickening and return of the liquid phase thus obtained into the process, whereby ground materials are mixed with recirculated extract and liquid phase obtained during extracted pulp thickening is mixed with fresh extractant being fed for extracting. In one of the versions low-succulent raw materials are infused and thickened with a part of the recirculated extract to obtain one product - infused extract, and thickened pulp is mixed with the other part of the extract and fed for extracting. In the second version first product - natural juice is extracted from succulent raw materials and flown down pulp is mixed with a part of extract and fed for extracting to obtain the second product - extract of flown down pulp. Raw materials are ground into dispersion particles of sizes greater than those of perforations in the permeable inner tube being used, within 0.05 to 5.0 mm. Porosity within 0.6 to 0.83 is maintained in the pulp fed to the extractor. Relation between the dose of fresh extractant being used and the volume of processed raw materials is maintained within 0.33 to 1.0.

EFFECT: increased rate of component extraction from raw materials, increased unit capacity for extracted components with reduced number of processing steps and units of equipment to be used.

17 cl, 6 dwg, 1 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: method of obtaining galacturonans from raw vegetable material involves preliminary raw material processing by aqueous formalin solution, maturing in acidified water, extraction by aqueous ammonium oxalate solution, extract centrifugation, adding HCl to a specified content, maturing in specified conditions, neutralisation, filtration, extract concentration in ultrafiltration column with simultaneous dialysis, and lyophilic drying of target product.

EFFECT: high-quality galacturonans with antiseptic effect.

2 cl, 2 tbl, 4 ex

FIELD: medicine; pharmacology.

SUBSTANCE: extract crushed shelf fungus using hot water under certain conditions, filter all extract with reception of an extract of the first step of extraction and a constrictor which extract under certain conditions with obtaining of extract of the second step of extraction, unite extracts.

EFFECT: increase of content of extractive substances in water shelf fungus extract.

1 tbl, 1 ex

FIELD: medicine; pharmacology.

SUBSTANCE: method for ferutinine obtaining, comprising in daucane ethers extraction from Ferula spp., base hydrolysis of daucane esters resulting in obtaining jaeschkenadiol, its etherification with p-pivoloyloxybenzoic acid resulting in obtaining p-pivoloylferutinine, followed by p-pivoloylferutinine hydrolysis to ferutinine. The two latter substances can be applied in cosmetic and/or dermatologic compositions.

EFFECT: elimination of concurrent reactions and increase in ferutinine yield for application to cosmetic and dermatologic compositions.

9 cl, 10 ex

FIELD: medicine; veterinary science.

SUBSTANCE: prevention of carcinogenic action of diethyl nitrosamine in experimental animals is ensured by daily introduction of anticarcinogen combined with feed. Anticarcinogen is presented with powdered phytoadaptogen "Chagovit" dosed 50 mg/kg within 9 months. On the 5th day, this therapy is added with introduction of diethyl nitrosamine combined with drink dosed 100 mg/l within the first 4 months.

EFFECT: lower rate of neoplastic changes in liver and oesophagus tissues, higher lifetime and survival rate of animals ensured by lower level of lipid peroxidation and improved activity of antioxidant enzymes.

2 ex, 2 tbl, 8 dwg

FIELD: medicine.

SUBSTANCE: there is disclosed pharmaceutical product as prepared solution. The pharmaceutical product comprises a reservoir filled with dissolved zoledronic acid or its pharmaceutically acceptable salt. At least the internal surface of said reservoir contains plastic material that is polyolefin. The product is exposed to thermal sterilisation, preferentially to moist thermal sterilisation. Besides the product can contain a buffer component, preferentially the buffer organic base. Additionally, the product can contain an isotonic component, preferentially mannitol. The invention provides product sterilisation at high temperature 121°C during 150 minutes without visible deformations and damages of sealed integral reservoir, as well as decomposition of pharmaceutical substance.

EFFECT: thermal stability allows for multiple sterilisation cycle that leads to sterility assurance level at least 10-12.

38 cl, 19 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products and concerns pharmaceutical composition for treatment of the diseases associated with urokinase activator of plasminogen (u-PA) and/or with receptor of activator of urokinase plasminogen (u-PAR), containing: (i) amidino-, hydroxyamidino-, guanydino- and/or hydroxyguanydinophenylalanine derivative as an active material, (ii) mixed alcohol and polyol, and (iii) aqueous phase containing buffer solution. There is also disclosed stabilisation method of pharmaceutical composition.

EFFECT: physical and chemical stability.

25 cl, 6 dwg, 1 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: according to the invention, method involves introduction of Paramycin 42 ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779). In addition, the invention refers to applications of CCI-779 in producing a medicinal agent for amphicyte lymphoma.

EFFECT: application of the invention ensures amphicyte lymphoma treatment.

9 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical products, particularly to application of compound of formula I where A stands for O, R stands for hydrogen or lower alkyl, and Z stands for O to prepare a medicinal agent for treatment of cancer disease chosen from primary cancer of Fallopian tube; primary peritoneal cancer and colorectal cancer progressing after Irinotecan therapy. Besides the invention concerns the pharmaceutical composition including specified compound, therapy of specified diseases and commercial package. formula (I).

EFFECT: agent is characterised with improved effectiveness.

13 cl, 7 ex

FIELD: medicine.

SUBSTANCE: there is described oral pharmaceutical composition containing 9,10-dehydroepothilone combined with a pharmaceutically acceptable carrier. According to the second version, the oral pharmaceutical composition contains trans-9,10-degihydroepothilone D and a pharmaceutically acceptable carrier containing hydroxypropyl-β-cyclodextrine, ethanol and propylene glycol. The concentrate for injection contains 9,10-degihydroepothilone D in the pharmaceutically acceptable carrier.

EFFECT: good bioavailability of epothilone D.

21 cl, 4 ex

FIELD: medicine.

SUBSTANCE: prevention of carcinogenic action of diethyl nitrosamine in experimental animals is ensured by introduction of kaskorutol dosed 0.4 g/kg within 9 months as an anticarcinogen, while diethyl nitrosamine is introduced in a dose 100 mg/l 5 days after introduction of kaskorutol within 4 months.

EFFECT: reduced carcinogenic action of diethyl nitrosamine due to inhibition of blastomogenic process, lowered level of lipid peroxidation, improved activity of antioxidant enzymes.

2 tbl, 8 dwg, 1 ex

FIELD: pharmacy.

SUBSTANCE: antineoplastic preparation which coordination compound on the magnesium gluconate base wherein the ligands are chosen from the group consisting of γ-aminobutyric acid (GABA), 3-hydroxy-GABA, ethylendiaminotetraacetic acid and ethylenglycoltetraacetic acid or binary salt chosen from the group consisting of magnesium butyrogluconate, oxymagnesium butyrogluconate, magnesium glucarate-gluconate, calcium butyrogluconate, calcium oxybutyrogluconate, calcium glucarate-gluconate and their combinations.

EFFECT: claimed preparations exert the apoptotic and antiproliferative effect retaining the civilised cells.

4 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to oncology, and concerns development of a medicinal agent for angiogenesis control. It is ensured by application of sphingosine-1-phosphate receptor agonist representing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3 diol, or its hydrochloride, or phosphate. The present invention also can include these substances combined with chemotherapeutic agents.

EFFECT: invention provides angiogenesis regulation including inhibition of uncontrolled neoangiogenesis, particularly in solid tumour therapy.

9 cl, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to oncology, and concerns development of a medicinal agent for angiogenesis control. It is ensured by application of sphingosine-1-phosphate receptor agonist representing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3 diol, or its hydrochloride, or phosphate. The present invention also can include these substances combined with chemotherapeutic agents.

EFFECT: invention provides angiogenesis regulation including inhibition of uncontrolled neoangiogenesis, particularly in solid tumour therapy.

9 cl, 7 dwg

FIELD: medicine.

SUBSTANCE: composition contains the plant or plant pieces, juice, dry extract, ethanolic extract, aqueous alcoholic extract or glycol extract of herb Equisetum in amount 0.1 to 15 wt %.

EFFECT: composition can be applied for treatment of such specific damages of nail structure as reduced strength, onychoschizis and nail fragility as a local preparation for nails.

22 cl, 11 ex, 2 tbl, 2 dwg

Up!